Pfizer Inc. $PFE Shares Sold by Glenview Trust Co

Glenview Trust Co cut its stake in Pfizer Inc. (NYSE:PFE) by 4.5% in the third quarter, Holdings Channel.com reports. The firm owned 443,853 shares of the biopharmaceutical company’s stock after selling 20,981 shares during the quarter. Glenview Trust Co’s holdings in Pfizer were worth $11,309,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after acquiring an additional 10,198,330 shares during the last quarter. Geode Capital Management LLC increased its position in Pfizer by 1.4% during the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after purchasing an additional 1,820,634 shares during the last quarter. Norges Bank purchased a new position in Pfizer during the second quarter worth about $2,270,157,000. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 2.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after purchasing an additional 1,135,457 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in shares of Pfizer by 2.0% in the 2nd quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock valued at $1,172,980,000 after buying an additional 950,239 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.4%

NYSE PFE opened at $27.58 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market cap of $156.78 billion, a price-to-earnings ratio of 20.28 and a beta of 0.47. The firm has a 50 day simple moving average of $25.84 and a 200-day simple moving average of $25.23. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.63 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is presently 126.47%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PFE. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Bank of America reduced their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Finally, Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.00.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.